Cancer Therapeutics and Discovery Targets

Technology Transfer Contacts

(technologies available for licensing)

Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11

TECH ID

TITLE

LEAD INVENTOR

CONTACT

 02-15

ATR kinase: a novel cellular target for anti- retroviral drug discovery and therapy

Patent No. US7736848B2; Summary

Anna Marie Skalka

Natalia Shalginskikh

 03-13

Targeted therapy for ovarian cancer: Anti-Mullerian Inhibiting Substance Type II Receptor (MISIIR) Immunoconjugates to Detect and Treat Cancer

Patent No. US7781568B2;

Patent No. US8198411B2; Summary

  Gregory Adams

Tatiana Venkova

 06-16

Treatment of diseases associated with aberrant ciliary function

Patent No. US8685658B2; Summary

 Erica Golemis

Natalia Shalginskikh

 07-05

Compositions and Methods for Altering Pancreas and Liver Functions 

Patent No. US8329467B2

 Kenneth Zaret 

Tatiana Venkova

 07-29

Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and antiviral agents

Patent No. US8557241B2; Summary

 Luis Sigal 

Natalia Shalginskikh

 07-40

EFGR/NEDD9/TGF-β Interactome and Methods for the Identification of Agents for the Treatment of Hyperproliferative Disorders

Patent No.US10450613B2; Summary

  Igor Astsaturov 

Natalia Shalginskikh

 104-JT

Methods to Treat Hepatitis B and other Liver Disorders

Patent No. US8748373B2; Summary

 John Taylor

Natalia Shalginskikh

 108-YM

Synergistic Cytotoxic Effects of 5-Fluorouracil Derivatives and 5-Hydroxymethyluracil Derivatives

Patent No. US8617540B2

 Yoshihiro Matsumoto 

Natalia Shalginskikh

 114-EH

Method for the Treatment of Lymphangioleiomyomatosis (LAM)

Patent No. US8530457B2

 Elizabeth Henske

Natalia Shalginskikh

115-IR

Use of Synthetic Peptides for the Prevention and Treatment of Breast Cancer

Patent No. US8969304B2

 Irma Russo 

Natalia Shalginskikh

 151-EG

Combination Therapy for the Treatment of Cancer: Aurora  A Kinase Inhibitors and Dasatinib

Patent No. US9101631B2; Summary

 Erica Golemis

Natalia Shalginskikh

 196-MM

Modulators of Hsp70/ Dnak Function

Patent No. US9296687B2

 Maureen Murphy 

Natalia Shalginskikh

 222-HB

A Highly Specific Antibody Targeting Tumor Endothelial Marker 7R

Patent No. US8883978B2; Summary

Patent No. US9534050B2

 Hossein Borghaei 

Tatiana Venkova

 243-MC

Targeting of Cytochrome CYP1B1 in the Treatment of Head and Neck and Lung Cancers

Patent No. US9101603B2; Summary

 Margie Clapper

Natalia Shalginskikh

 250-MA

New Drug Target Site of HIV Integrase for AIDS Therapy

Patent No. US9533040B2; Summary

 Mark Andrake 

Natalia Shalginskikh

264-JP

Small Molecule Inhibitors of ACK1 for Treating Cancer and Dyskinesia in Parkinson’s Disease

Patent No. US8,658,655  B2Summary

Jeffrey Peterson

Tatiana Venkova

 276-GA

Rationally-designed Anti-Mullerian Inhibiting Substance Type II Receptor Antibodies

Patent No. US9611321B2; Summary

 Gregory Adams

Inna Khartchenko

 280-TY

Combination Inhibition of the Vitamin D Receptor and DNA Replication in the Treatment of Cancer

Patent No. US9265787B2; Summary

 Timothy Yen

Tatiana Venkova

 311-AB

Combination of DNA Repair Inhibition With Bendamustine or Gemcitabine in the Treatment of Cancer

Patent No. US8927516B2

 Alfonso Bellacosa 

Natalia Shalginskikh

 314-VK

New Anticancer Zinc Chetatin Agents for Therapy of Advanced Prostate Cancer

Patent No. US9320736B2; Summary

 Vladimir Kolenko 

Natalia Shalginskikh

 326-NB

Sensitization of Cancer Cells to DNA Damage by Inhibiting Kinases Essential for DNA Damage Checkpoint Control

Patent No. US9421203B2; Summary

 Timothy Yen

Tatiana Venkova

 337-ZY

Novel Treatment of Medulloblastoma by Inhibition of Leukotriene Synthesis and Activity

Patent No. US9616056B2; Summary

 Zeng-Jie Yang 

Natalia Shalginskikh

 346-AB

Novel Methods for Inhibiting Growth and Proliferation of Melanoma Cells

Patent No. US11077121B2; Summary

 Alfonso Bellacosa 

Natalia Shalginskikh

 349-IA

C-MYC as a Novel Biomarker of Cancer Therapeutic Efficacy

Patent No. US9993458B2; Summary

 Igor Astsaturov 

Natalia Shalginskikh

 370-AT

Novel Class of PARP-1 Blockers for the Treatment of Prostate and Renal Cancers

Patent No. US9993458B2; Summary

 Alexei Tulin 

Natalia Shalginskikh

 381-TY

Combined Inhibition of the Vitamin D Receptor and Poly (ADP) Ribose Polymerase-1 (PARP-1) in Cancer Therapy

Patent No. US9889141B2; Summary

Patent No. US10449200B2

Timothy Yen

Tatiana Venkova

 394-EG

Systems and Methods for Treating Patients Having a Genetic Predisposition to Develop Prostate Cancer

Published Application No.WO2017049023A1Summary

Patent No. US10724100B2 

Other Patent Applications Pending

 Erica Golemis

Tatiana Venkova

 404-WE

Prodigiosin Analogs as Cancer Therapeutics

Patent No. US10654801B2Summary

 Wafik El-Deiry 

Tatiana Venkova

 407-SB

Viral-Based Cancer Gene Therapy and Treatment of Influenza Infection Through Induction of Cell Death

Published Application No.WO2018009541A1; Summary

 Siddharth Balachandran 

Natalia Shalginskikh

 424-WE

MicroRNA as Targeting CDK4/6-Cell Cycle Pathways Treatment for Cancer

Published Application No.WO2018157026A1; Summary

 Wafik El-Deiry

Tatiana Venkova

 425-MA

Small Molecule Allosteric Inhibitors of HIV Integrase

 Published Application No.WO2018140762A1; Summary

 Mark Andrake

Natalia Shalginskikh

 426-SA

Methods For Diagnosis And Treatment Of Patients Having Solid Tumors

Published Application No.US20200232041A1; Summary

Sanjeevani Arora

Tatiana Venkova

 427-ZY

Cholesterol Synthesis Inhibitors Synergize with Smoothened Antagonist for  Treatment of Hedgehog Pathway Malignancies

 Published Application No.WO2018218114A1Summary

 Zeng-Jie Yang 

Natalia Shalginskikh

429-RD

Chimera of Bone Morphogenic Protein 2 and the Mullerian Inhibiting Substance Type II Receptor Binding Region of Mullerian Inhibiting Substance

Published Application No.US20200010523A1; Summary

 Roland Dunbrack

Tatiana Venkova

430-WE

Compounds For Repressing Cancer Cell Growth

Published Application No. US20190225614A1Summary

Wafik El-Deiry

Tatiana Venkova

431-WE

High EGFR Somatic Mutation Frequency Targeting the TK Domain in Colorectal Cancer Patients with Microsatellite Instability (MSI)

Published Application No.WO2018157032A1Summary

Wafik El-Deiry

Tatiana Venkova

432-WE

Dual Inhibition of CDK1 and HSP90 Destabilize HIF1a and Synergistically Induces Cancer Cell Death

Published Application No.US20180243306A1Summary

Patent No. US10729692B2 

Wafik El-Deiry

Tatiana Venkova

438-JD

Generating a Kinome Profile for Cancer Therapy

Published Application No.US2020046770A1Summary

James Duncan

Natalia Shalginskikh

 439-EC

Pancreatic Cancer Associated Desmoplastic Immune Checkpoint Inhibitor

Published Application No.WO2019074915A1Summary

Edna Cukierman

Natalia Shalginskikh

 441-JR

Development of a Panel of Markers Predicting Response of Breast Cancer Prevention

Published Application No.WO2019079167A1Summary

Jose Russo

Natalia Shalginskikh

 447-WE

TRAIL Upregulating miRNA with Apoptotic Activity

Published Application No.WO2019177928A1; Summary

Wafik El-Deiry

Tatiana Venkova

461-PA

Urinary DNA Detection for Monitoring of Urothelial Cancer

Published Application No.WO2019222325A1Summary

Philip Abbosh

Natalia Shalginskikh

462-PM

Combination of Sunitinib with Farnesyl-Transferase Inhibitors as a Next Generation Therapeutic Approach

Published Application No.WO2020092517A1;  Summary

Petr Makhov

Natalia Shalginskikh

469-ME

Radiotherapeutic Combination Therapy For Treatment of Cancer

Published Application No.WO2020145977A1

Martin Edelman

Tatiana Venkova

477-DC

A novel antibody for the treatment of ovarian and other cancers

Published Application No.WO2020167927A1

Denise Connolly

Natalia Shalginskikh

482-SB 

Protein Kinase  Inhibitors and Uses Thereof  for the Treatment of Diseases and Conditions

Published Application No. WO2020232190A1

Siddharth Balachandran

Natalia Shalginskikh

484-EC

Reagent/Drug(s) to Prevent NetricGI/NGLI Engagement

Published Application No. WO2020219854A1Summary

Edna Cukierman

Natalia Shalginskikh

485-JK

Using Chemical Biology to Enable Precision Immuno-Oncology

Published Application No. WO2020223273A2Summary

John Karanicolas

Tatiana Venkova

493-LW

Methods of Inhibiting Proliferation of Estrogen-Independent Cancer Cells

Patent No. US9677072B2Summary

Louis Weiner

Natalia Shalginskikh

494-AP

Novel Druggable Targets on the Interface of Oncogenic and Metabolic Pathways

Published Application No. WO2020243063A1Summary

Andrzej Ptasznik

Tatiana Venkova

498-PA

Azolium Salts for Treatment of Non-Muscle Invasive Bladder Cancer

Patent No. US11197873B2Summary

Philip Abbosh

Natalia Shalginskikh

499-JD

Combination Therapy for Treatment of Cancer (PROTACs and mTORC inhibitors) 

Published Application No. WO2021026349A1Summary

James Duncan

Natalia Shalginskikh

520-AB

TDG inhibitors for the treatment of cancer and other diseases

Published Application No. WO2022047288A1Summary

Alfonso Bellacosa

Natalia Shalginskikh

522-MC

Estrogen Metabolite Levels and EGFR Mutations in Lung Cancer Risk Stratification and Treatment

Published Application No. WO2021142408A1

Margie Clapper

Natalia Shalginskikh

534-JR

Treatment of females having BRCA1/2 mutations with human chorionic gonadotropin to reduce the risk of developing breast cancer

Published Application No. WO2022125417A1;  Summary

Jose Russo

Natalia Shalginskikh

536-EK

Treatment Of Non-Alcoholic Steatohepatitis (NASH) With IL-27 Antibody

Published Application No. US20220089714A1

Ekaterina Koltsova

Natalia Shalginskikh

541-JW

Treatment of Integrin-Related Disorders With Stapled Peptides

Published Application No. WO2022/165127A2;  Summary

Jinhua Wu

Tatiana Venkova

543-JRW

Compositions And Methods For Regulating EGFR Amplification In Cancer Cells For Improving Efficacy Of EGFR-Targeted Anti-Cancer Agents

 

 

Published Application No. WO2021097464A1

Johnathan R Whetstine

 

 

Tatiana Venkova

544-JK

Compositions and Methods for Modulation of Antibody Activity

Patent Pending; Summary in 485-JK.

John Karanicolas

Tatiana Venkova

546-JT

Malignant Mesothelioma Susceptibility as a Result of Germline Gene Alteration

Patent Pending; Summary

Joseph Testa

Tatiana Venkova

550-PA

Personalized therapeutic cancer vaccines based on aberrantly translated introns for patients with tumors harboring
SETD2 mutations

Patent Pending; Summary

Philip Abbosh

Natalia Shalginskikh

552-JD

Combining ABCB1 inhibitors with PROTAC therapies to improve therapeutic responses

Patent Pending; Summary

James Duncan

Natalia Shalginskikh

554-JC

Novel PAK1-Selective Degrader for Treatment of Cancer

Patent Pending

Jonathan Chernoff

Tatiana Venkova

560-JB

Novel Druggable Target in NMN and NAD+ Biosynthesis Pathways in Cancer and Other Diseases.

Patent Pending

Johnvesly Basappa

Tatiana Venkova

563-IA

TMEM16F is the key regulator of trogocytosis in cancer-associated fibroblasts and is a target for the existing anti-helminthic drugs.

Patent Pending

Igor Astsaturov

Natalia Shalginskikh

564-JRW

Targeting Genomic Anomalies in Mixed Lineage Leukemia.

Patent Pending

Johnathan Whetstine

Tatiana Venkova

565-CD

Targeting Senescence-like Leukemia Cells: A Novel Therapeutic Strategy to Eliminate Minimal Residual Disease.

Patent Pending

Cihangir Duy

Tatiana Venkova

566-JB

Novel Oncogenic Driver and Therapeutic Target in Mantle Cell Lymphoma.

Patent Pending

Johnvesly Basappa

Tatiana Venkova

567-ZY

Thyroid hormone treats medulloblastoma

Patent Pending; Summary

Zeng-Jie Yang

Natalia Shalginskikh